Skip to main content
  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

  • Home
  • About this Journal
    • General Statistics
    • Editorial Board
    • Editors
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
    • Acknowledgment of Reviewers
    • Clinical Implications
    • Clinical-Pathological Conferences
    • Controversies in Hypertension
    • Editors' Picks
    • Guidelines Debate
    • Meeting Abstracts
    • Recent Advances in Hypertension
    • SPRINT Trial: the Conversation Continues
  • Resources
    • Instructions to Reviewers
    • Instructions for Authors
    • →Article Types
    • → Submission Guidelines
      • Research Guidelines
        • Minimum Information About Microarray Data Experiments (MIAME)
      • Abstract
      • Acknowledgments
      • Clinical Implications (Only by invitation)
      • Conflict(s) of Interest/Disclosure(s) Statement
      • Figure Legends
      • Figures
      • Novelty and Significance: 1) What Is New, 2) What Is Relevant?
      • References
      • Sources of Funding
      • Tables
      • Text
      • Title Page
      • Online/Data Supplement
    • →Tips for Easier Manuscript Submission
    • → General Instructions for Revised Manuscripts
      • Change of Authorship Form
    • → Costs to Authors
    • → Open Access, Repositories, & Author Rights Q&A
    • Permissions to Reprint Figures and Tables
    • Journal Policies
    • Scientific Councils
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
  • Facebook
  • Twitter

  • My alerts
  • Sign In
  • Join

  • Advanced search

Header Publisher Menu

  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

Hypertension

  • My alerts
  • Sign In
  • Join

  • Facebook
  • Twitter
  • Home
  • About this Journal
    • General Statistics
    • Editorial Board
    • Editors
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
    • Acknowledgment of Reviewers
    • Clinical Implications
    • Clinical-Pathological Conferences
    • Controversies in Hypertension
    • Editors' Picks
    • Guidelines Debate
    • Meeting Abstracts
    • Recent Advances in Hypertension
    • SPRINT Trial: the Conversation Continues
  • Resources
    • Instructions to Reviewers
    • Instructions for Authors
    • →Article Types
    • → Submission Guidelines
    • →Tips for Easier Manuscript Submission
    • → General Instructions for Revised Manuscripts
    • → Costs to Authors
    • → Open Access, Repositories, & Author Rights Q&A
    • Permissions to Reprint Figures and Tables
    • Journal Policies
    • Scientific Councils
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
Scientific Contributions

How Far Should Salt Intake Be Reduced?

Feng J. He, Graham A. MacGregor
Download PDF
https://doi.org/10.1161/01.HYP.0000102864.05174.E8
Hypertension. 2003;42:1093-1099
Originally published December 11, 2003
Feng J. He
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Graham A. MacGregor
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Info & Metrics
  • eLetters

Jump to

  • Article
    • Abstract
    • Methods
    • Results
    • Discussion
    • Acknowledgments
    • References
  • Figures & Tables
  • Info & Metrics
  • eLetters
Loading

Abstract

The current public health recommendations are to reduce salt intake from 9 to 12 g/d to 5 to 6 g/d. However, these values are based on what is feasible rather than the maximum effect of salt reduction. In a meta-analysis of longer-term trials, we looked at the dose response between salt reduction and fall in blood pressure and compared this with 2 well-controlled studies of 3 different salt intakes. All 3 studies demonstrated a consistent dose response to salt reduction within the range of 12 to 3 g/d. A reduction of 3 g/d predicts a fall in blood pressure of 3.6 to 5.6/1.9 to 3.2 mm Hg (systolic/diastolic) in hypertensives and 1.8 to 3.5/0.8 to 1.8 mm Hg in normotensives. The effect would be doubled with a 6 g/d reduction and tripled with a 9 g/d reduction. A conservative estimate indicates that a reduction of 3 g/d would reduce strokes by 13% and ischemic heart disease (IHD) by 10%. The effects would be almost doubled with a 6 g/d reduction and tripled with a 9 g/d reduction. Reducing salt intake by 9 g/d (eg, from 12 to 3 g/d) would reduce strokes by approximately one third and IHD by one quarter, and this would prevent ≈20 500 stroke deaths and 31 400 IHD deaths a year in the United Kingdom. The current recommendations to reduce salt intake from 9 to 12 g/d to 5 to 6 g/d will have a major effect on blood pressure and cardiovascular disease but are not ideal. A further reduction to 3 g/d will have a much greater effect and should now become the long-term target for population salt intake worldwide.

  • sodium, dietary
  • blood pressure
  • dose response
  • cardiovascular diseases

High blood pressure is the most important risk factor for cardiovascular disease.1 A recent World Health Organization report states that elevated blood pressure alone causes ≈50% of cardiovascular disease worldwide.1 A more recent article in The Lancet demonstrates that nonpersonal health interventions, including government action to stimulate a reduction in the salt (sodium chloride) content of processed foods, are cost-effective ways to limit cardiovascular disease and could avert >21 million disability-adjusted life years per year worldwide.2 A recent meta-analysis of 1 million adults in 61 prospective studies demonstrates that the relation between blood pressure and cardiovascular risk is much stronger than previously estimated.3 Much evidence from epidemiologic,4 migration,5 intervention,6 genetic,7 and animal8 studies suggests that salt intake plays an important role in regulating blood pressure. Several meta-analyses of randomized, salt reduction trials have been published in the last few years.9–12 However, most of the previous meta-analyses included trials of very short duration (eg, 5 days) and included trials with a short-term salt loading followed by salt deprivation (eg, from 20 to less than 1 g/d) for only a few days.9,11 These short-term salt loading and salt depletion experiments are not appropriate for helping to inform public health policy, which is for a more modest reduction in salt intake over a more prolonged period of time. A more recent meta-analysis by Hooper et al12 is an important attempt to look at whether long-term salt reduction (ie, >6 months) in randomized trials causes a fall in blood pressure. However, most trials included in this meta-analysis only achieved a very small reduction in salt intake, and on average, salt intake was reduced by only 2 g/d. It is therefore not surprising that there was only a small, but still highly significant, fall in blood pressure. Furthermore, an important point as to whether there is a dose response to salt reduction has been overlooked in this meta-analysis.

Salt intake in many countries is between 9 and 12 g/d. The current World Health Organization recommendations for adults are to reduce salt intake to 5 g/d or less,13 and the UK14 and US recommendations15 are 6 g/d or less. However, these recommendations are based on what is feasible and not on what might have been the maximum impact on blood pressure and cardiovascular disease. Recent evidence suggests that these levels, although they might be feasible, are too high.

Studies in experimental animals have shown a clear dose response between salt intake and blood pressure: the higher the salt intake, the higher the blood pressure.16 A recent study in chimpanzees, the animal species closest to humans with 98.4% genetic identity, demonstrated a dose response when salt was increased from their usual intake of 0.5 g/d to 5, 10, and 15 g/d.8 In humans, it is difficult to conduct such trials, particularly to keep individuals on a low-salt diet long term because of the widespread presence of salt in nearly all processed, restaurant, canteen, and fast foods. However, 2 well-controlled trials have studied 3 salt intakes (ie, from 11.2, 6.4, to 2.9 g/d in 1 trial17 and from 8.3, 6.2, to 3.8 g/d in the other18), and both showed a clear dose response to salt reduction.

To study this dose-response relation further, we reanalyzed a recent meta-analysis of randomized, longer-term, salt reduction trials19 and looked at the dose-response relation and compared this with the 2 well-controlled studies of 3 salt intakes to try to determine the optimal salt intake that would have the maximum impact on blood pressure, strokes, and ischemic heart disease (IHD).

Methods

The methods of the meta-analysis were reported in detail elsewhere19 and are summarized here. The inclusion criteria were as follows:

  1. Random allocation to either a reduced salt intake or usual salt intake (ie, control).

  2. No concomitant interventions in either group.

  3. Net reduction in 24-hour urinary sodium ≥40 mmol (2.4 g of salt per day). Net reduction in 24-hour urinary sodium was calculated as UNa (Post)−UNa (Pre) for crossover trials, where UNa (Post) designates urinary sodium on the reduced salt intake and UNa (Pre) designates urinary sodium on the usual salt intake. In parallel trials, the net change in urinary sodium was calculated as {[UNa (Post)−UNa (Pre)]reduced salt group}−{[UNa (Post)−UNa (Pre)]control group}.

  4. Duration of salt reduction must have been for 4 or more weeks.

  5. Study participants were not children or pregnant.

Mean effect sizes were calculated by weighting each trial by the inverse of the variance. Weighted linear regression was used to examine the dose-response relation between the change in 24-hour urinary sodium and the change in blood pressure.20 From the regression line, we calculated the predicted falls in blood pressure with a reduction of 3, 6, and 9 g/d in salt intake.

Results

Trials in Hypertensive Individuals

The characteristics of individual trials included in the meta-analysis were reported in detail elsewhere19 and are summarized here. Seven hundred thirty-four hypertensive individuals were studied in 17 trials.17,18,21–35 Median age was 50 years (ranging from 24 to 73 years). The study duration varied from 4 weeks to 1 year (median, 6 weeks). The median 24-hour urinary sodium on the usual salt intake was 161 mmol (9.5 g of salt per day), ranging from 125 to 191 mmol (7.4 to 11.2 g of salt per day), and on the reduced salt intake it was 87 mmol (5.1 g of salt per day), ranging from 57 to 117 mmol (3.4 to 6.9 g of salt per day). The median net change in 24-hour urinary sodium was −78 mmol (4.6 g of salt per day), ranging from −53 to −117 mmol (3.1 to 6.9 g of salt per day).

The pooled estimates of changes in blood pressure were −5.0±0.4 mm Hg (mean±SEM, P<0.001; 95% confidence interval [CI], −5.8 to −4.2 mm Hg) for systolic and −2.7±0.2 mm Hg (P<0.001; 95% CI, −3.2 to −2.3 mm Hg) for diastolic pressure.

To examine whether there was a dose-response relation between the changes in 24-hour urinary sodium and the changes in blood pressure, we performed weighted linear regression and assumed a zero intercept. The assumption for using this model was that the absence of a change in urinary sodium would be associated with no change in blood pressure, ie, all other factors being equal between 2 randomized treatments. The results showed a significant dose response to salt reduction (P<0.001 for both systolic and diastolic pressures; Figure 1). A reduction of 50 mmol/d (3 g/d) in salt intake predicts a fall in blood pressure of 3.6/1.9 mm Hg. A reduction of 100 mmol/d (6 g/d) predicts a fall in blood pressure of 7.1/3.9 mm Hg. A reduction of 150 mmol/d (9 g/d) in salt intake would cause a fall in blood pressure of 10.7/5.8 mm Hg.

Figure1
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 1. Relation between the net change in 24-hour urinary sodium excretion and blood pressure in the meta-analysis. Open circles represent normotensives and solid circles represent hypertensives. The slope is weighted by the inverse of the variance of the net change in blood pressure. The size of the circle is proportional to the weight of the trial.

Trials in Normotensive Individuals

Two thousand two hundred twenty normotensive individuals were studied in 11 trials.18,35–43 Median age was 47 years (ranging from 22 to 67 years). The study duration varied from 4 weeks to 3 years (median, 4 weeks). The median 24-hour urinary sodium on the usual salt intake was 154 mmol (9.1 g of salt per day), ranging from 128 to 200 mmol (7.5 to 11.8 g of salt per day), and on the reduced salt intake it was 82 mmol (4.8 g of salt per day), ranging from 56 to 135 mmol (3.3 to 7.9 g of salt per day). The median net change in 24-hour urinary sodium was −74 mmol (4.4 g of salt per day), ranging from −40 to −118 mmol (2.4 to 6.9 g of salt per day).

The pooled estimates of changes in blood pressure were −2.0±0.3 mm Hg (P<0.001; 95% CI, −2.6 to −1.5 mm Hg) for systolic and −1.0±0.2 mm Hg (P<0.001; 95% CI, −1.4 to −0.6 mm Hg) for diastolic pressure. The dose-response analysis with fixing the intercept showed a significant dose response to salt reduction (P<0.001 for systolic and P<0.05 for diastolic pressures; Figure 1). A reduction of 3, 6, and 9 g/d in salt intake predicts a fall in blood pressure of 1.8/0.8, 3.6/1.7, and 5.4/2.5 mm Hg, respectively.

Trials in All Individuals

When all individuals were grouped together, there were 2954 subjects (25% were hypertensives). Median age was 49 years (ranging from 22 to 73 years). The study duration varied from 4 weeks to 3 years (median, 5 weeks). The pooled estimates of changes in blood pressure were −2.9±0.2 mm Hg (P<0.001; 95% CI, −3.4 to −2.5 mm Hg) for systolic and −1.7±0.2 mm Hg (P<0.001; 95% CI, −2.0 to −1.4 mm Hg) for diastolic pressure. The dose-response analysis with fixing the intercept showed a significant dose response to salt reduction (P<0.001 for systolic and P<0.001 for diastolic pressures). A reduction of 3, 6, and 9 g/d in salt intake predicts a fall in blood pressure of 2.5/1.4, 5.0/2.8, and 7.5/4.2 mm Hg, respectively.

Dose Response Between Salt Intake and Blood Pressure in Our Previous Double-Blind Study and the DASH-Sodium Study

The best way to study the dose-response relation between salt intake and blood pressure is to look at the blood pressure responses to several levels of salt intake for a long term. So far, there are only 2 well-controlled trials that studied 3 salt intakes, each for 4 weeks. One is our double-blind study in 19 patients with untreated essential hypertension,17 and the other is the Dietary Approaches to Stop Hypertension (DASH)-Sodium study,18 in which 79 untreated hypertensives and 116 normotensives were studied on the normal American diet, and 81 untreated hypertensives and 121 normotensives were studied on the DASH diet.

In our double-blind study with 3 salt intakes, the blood pressure decreased by 8/5 mm Hg when salt intake, as judged by 24-hour urinary sodium, changed from 190 to 108 mmol/24 h (11.2 to 6.4 g/d), and the blood pressure decreased by 8/4 mm Hg when salt intake changed from 108 to 49 mmol/24 h (6.4 to 2.9 g/d).17 The DASH-Sodium study showed that in all individuals (ie, both hypertensives and normotensives) who were studied on the normal American diet, the blood pressure decreased by 2.1/1.1 mm Hg when salt intake changed from 141 to 106 mmol/24 h (8.3 to 6.2 g/d) and by 4.6/2.4 mm Hg when salt intake changed from 106 to 64 mmol/24 h (6.2 to 3.8 g/d).18 In those who were studied on the DASH diet, the blood pressure decreased by 1.3/0.6 mm Hg when salt intake changed from 144 to 107 mmol/24 h (8.5 to 6.3 g/d) and by 1.7/1.0 mm Hg when salt intake changed from 107 to 67 mmol/24 h (6.3 to 3.9 g/d).18

To study the dose-response relation between salt intake and blood pressure, we performed linear regression analysis on these 2 studies by using the mean 24-hour urinary sodium and mean blood pressure at 3 salt intakes. For the purpose of comparison, we included only a subgroup of hypertensive and normotensive individuals who were studied on the normal American diet in the DASH-Sodium study. As shown in Figure 2, the 2 studies showed a very similar dose-response relation between salt intake and blood pressure. Within the range of 11.2 to 2.9 g of salt per day, the lower the salt intake, the lower the blood pressure. In patients with essential hypertension, a reduction of 3, 6, and 9 g/d in salt intake predicts a fall in blood pressure of 5.6/3.2, 11.2/6.4, and 16.8/9.6 mm Hg, respectively, in the double-blind, salt reduction study. In the DASH-Sodium study, the same reductions in salt intake predict a fall in blood pressure of 5.3/2.9, 10.5/5.7, and 15.8/8.6 mm Hg, correspondingly. The DASH-Sodium study also showed that in normotensive individuals, there was a dose response to salt reduction (Figure 2). A reduction of 3, 6, and 9 g/d in salt intake predicts a fall in blood pressure of 3.5/1.8, 7.0/3.5, and 10.5/5.3 mm Hg, respectively, in normotensives.

Figure2
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 2. Dose-response relation between 24-hour urinary sodium and blood pressure in the double-blind salt reduction study and the DASH-Sodium study.

Comparison of the Dose-Response Relation Among 3 Studies

To compare the dose-response relation among 3 studies, we superimposed the regression lines found in the 2 studies with 3 salt intakes on our meta-analysis (Figure 3). There was a similar dose response in all 3 studies. However, the regression line from our meta-analysis was flatter. This is not surprising, because some less well-controlled studies were included in the meta-analysis, and the diversity of patients recruited to different trials (eg, age, ethnic group, baseline blood pressure and potassium intake) might also have affected the blood pressure responses. Table 1 shows the predicted falls in blood pressure with reductions of 3, 6, and 9 g/d of salt intake in 3 studies. A reduction of 3 g/d in salt intake would have an effect on blood pressure, but the effect would be doubled with a 6 g/d reduction and tripled with a 9 g/d reduction in salt intake.

Figure3
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 3. Comparison of the dose-response relation among 3 studies.

View this table:
  • View inline
  • View popup

TABLE 1. Predicted Falls in Blood Pressure With Salt Reduction in 3 Studies

Discussion

Our meta-analysis of randomized, longer-term, salt reduction trials demonstrates a dose response to salt reduction. More importantly, the dose response found in our meta-analysis is consistent with the dose response found in the 2 well-controlled trials with 3 salt intakes. Within the range of 12 to 3 g of salt per day, the lower the salt intake, the lower the blood pressure. The current public health recommendations to reduce salt intake from 9 to 12 g/d to 5 to 6 g/d will have a major effect on blood pressure but are no means ideal. A further reduction to 3 g of salt per day will have a much greater effect on blood pressure.

One important point is that it is not clear from the 3 studies whether the dose response to salt reduction is linear or nonlinear. In hypertensives, both the DASH-Sodium study and our double-blind study of 3 salt intakes showed a nonlinear dose response for systolic pressure, ie, a steeper dose response at a lower level of salt intake. In other words, for a given reduction in salt intake, the fall in systolic blood pressure is larger when salt intake is at a lower level. However, for diastolic blood pressure in both the DASH-Sodium study and our double-blind study, the dose-response relation appears to be linear, and in the DASH-Sodium study in normotensives, there appears to be a linear dose response for both systolic and diastolic blood pressure.

For the purpose of comparison, only subgroup data of the DASH-Sodium study were included in our analyses. It is of note that the overall results of the DASH-Sodium study showed a nonlinear dose response to salt reduction both on the normal American diet and on the DASH diet, indicating that salt reductions have greater effects on blood pressure with salt intake at lower levels. In our meta-analysis, we assumed a linear relation between the change in 24-hour urinary sodium and the change in blood pressure. This, if anything, would underestimate the effect of salt reduction on blood pressure at lower levels of salt intake if the dose-response relation were nonlinear.

The recent UK National Diet and Nutrition Survey, which was carried out between 2000 and 2001 in a nationally representative sample of 1495 adults aged 19 to 64 years, showed that 24-hour urinary sodium was 187 mmol (11.0 g/d of salt) for men and 139 mmol (8.1 g/d of salt) for women.44 However, 24-hour urinary sodium is an underestimate of dietary salt intake. A study by Pietinen45 showed that the 24-hour urinary sodium was, on average, 93% of dietary salt intake. Therefore, the average salt intake in the United Kingdom is actually between 8.7 and 11.8 g/d. A conservative estimate of the impact on cardiovascular disease (ie, from the falls in blood pressure in all individuals in the meta-analysis) indicates that a reduction of 3 g/d in salt intake would result in a fall in blood pressure of 2.5/1.4 mm Hg, and this would reduce strokes by 12% (estimated from systolic) to 14% (from diastolic) and ischemic heart disease (IHD) by 9% to 10%.3 In the United Kingdom, the total number of stroke deaths is 60 666 per year, and the total number of IHD deaths is 124 037 per year.46 Therefore, a reduction of 3 g/d in salt intake would prevent ≈7300 to 8300 stroke deaths and 10 600 to 12 400 IHD deaths per year. As shown in Table 2, the effects on strokes and IHD would be almost doubled if salt intake were reduced by 6 g/d and tripled with a 9 g/d reduction. A reduction of 9 g/d in salt intake (eg, from 12 to 3 g/d) would result in a fall in blood pressure of 7.5/4.2 mm Hg, and this would reduce strokes by approximately one third and IHD by one quarter. In the United Kingdom, this would prevent ≈20 500 stroke deaths and 31 400 IHD deaths per year. These numbers of stroke and IHD deaths prevented are likely to be an underestimate, because the falls in blood pressure in the much better controlled DASH-Sodium study18 and our double-blind study17 are larger and would have an even greater impact.

View this table:
  • View inline
  • View popup

TABLE 2. Predicted Reductions in Stroke and IHD Deaths With Reductions in Salt Intake

It is important to note that even in normotensives alone, salt reductions would have large effects on stroke and IHD. A reduction of 3 g/d in salt intake would lower blood pressure by 1.8/0.8 mm Hg, and this would reduce strokes by 9% and IHD by 6% in normotensives alone. A reduction of 6 g/d would reduce strokes by 17% and IHD by 12%, and a reduction of 9 g/d would reduce strokes and IHD by 24% and 18%, respectively, in normotensives.

In our article, we reported the reductions in blood pressure, stroke, and IHD death with reductions of 3, 6, and 9 g/d in salt intake. The long-term target should be to reduce salt intake to 3 g/d. Therefore, if individuals have a salt intake of 12 g/d, then they need to reduce salt intake by 9 g/d, and if individuals have a salt intake of 9 g/d, then they need to reduce salt intake by 6 g/d. The effects of these reductions in salt intake on blood pressure, stroke, and IHD deaths are shown in Table 1 and Table 2.

The levels of salt intake in many countries are similar to those in the United Kingdom. The percentage reduction in stroke and IHD applies to many countries. Therefore, the reductions in stroke and IHD worldwide, if salt intake were reduced from the current intake of 9 to 12 g/d to the now-recommended levels of 5 to 6 g/d, would be immense. The effects on stroke and IHD would be much greater if salt intake were reduced further, ie, to 3 g/d.

Although we calculated only the numbers of stroke and IHD deaths that could be prevented with reductions in salt intake, the percentage reductions in stroke and IHD apply to the incidence as well. Approximately 50% of patients who suffer stroke or heart attack survive; therefore, there would be a proportionate reduction in the numbers of these people. This would result in a reduction in disability and major cost savings both to individuals, their families, and the Health Service. Furthermore, high blood pressure is an important risk factor for heart failure. A reduction in salt intake would therefore have a major effect on heart failure.

From our studies, it is not clear whether reducing salt intake to <3 g/d has a greater effect on blood pressure, because no randomized trials with a duration of 4 or more weeks have reduced salt intake to <3 g/d. However, the observational epidemiologic studies suggest that within the range of 14 to 0.01 g of salt per day, there is a dose response between salt intake and blood pressure, ie, the lower the salt intake, the lower the blood pressure.4,47 Despite the potential greater benefits of reducing salt intake to <3 g/d, it is currently impractical to achieve a reduction to <3 g/d, given the current amount of salt in processed foods that accounts for 75% to 80% of our salt intake.48

In conclusion, our meta-analysis of longer-term salt reduction trials and the 2 well-controlled studies with 3 salt intakes demonstrate a consistent dose-response relation between salt intake and blood pressure within the range of 12 to 3 g of salt per day. Importantly, the dose-response relation exists in both hypertensive and normotensive subjects. The current public health recommendations to reduce salt intake from 9 to 12 g/d to 5 to 6 g/d will have a major effect on blood pressure and cardiovascular disease but are not ideal. A reduction to 3 g of salt per day will have a much greater effect and should now become the long-term target for population salt intake worldwide.

Perspectives

The totality of evidence that links salt intake to blood pressure is now overwhelming. Current recommendations are to reduce salt intake from 9 to 12 g/d to 5 to 6 g/d. Our article demonstrates that although these reductions will have a major effect on blood pressure and cardiovascular disease, reducing salt intake further to 3 g/d will have additional large effects. Therefore, the target of 5 to 6 g/d should be seen as an interim target, and the long-term target for population salt intake worldwide should now be 3 g/d. This will be difficult, particularly because in most developed countries, 75% to 80% of salt intake now comes from salt added to processed foods. In our view, the strategy should be that the food industry should gradually reduce the salt concentration of all processed foods, starting with a 10% to 25% reduction, which is not detectable by consumers, and continuing a sustained reduction over the course of the next decade. This strategy has now been adopted in the United Kingdom by both the Department of Health and Food Standards Agency, and several leading supermarkets and food manufacturers have already started to implement such changes. Of all the dietary changes to try and prevent cardiovascular disease, a reduction in salt intake is the easiest change to make, because it can be done without the consumers’ knowledge but will require the cooperation of the food industry. Clearly, it would be helpful if individuals also reduced the amount of salt that they add to their own cooking or to their food. If this strategy were implemented and achieved and the 3 g/d target were reached throughout the world, there would be immense reductions in strokes, heart attacks, and heart failure.

Acknowledgments

We are very grateful to the DASH-Sodium Steering Committee for providing us with data necessary for calculating the dose-response relation.

  • Received June 23, 2003.
  • Revision received July 15, 2003.
  • Accepted October 10, 2003.

References

  1. ↵
    Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJL, and the Comparative Risk Assessment Collaborating Group. Selected major risk factors and global and regional burden of disease. Lancet. 2002; 360: 1347–1360.
    OpenUrlCrossRefPubMed
  2. ↵
    Murray CJL, Lauer JA, Hutubessy RCW, Niessen L, Tomijima N, Rodgers A, Lawes CMM, Evans DB. Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk. Lancet. 2003; 361: 717–725.
    OpenUrlCrossRefPubMed
  3. ↵
    Prospective studies collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for 1 million adults in 61 prospective studies. Lancet. 2002; 360: 1903–1913.
    OpenUrlCrossRefPubMed
  4. ↵
    Intersalt Cooperative Research Group. Intersalt: an international study of electrolyte excretion and blood pressure: results for 24-hour urinary sodium and potassium excretion. BMJ. 1988; 297: 319–328.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    Poulter N, Khaw KT, Hopwood BEC, Mugambi M, Peart WS, Rose G, Sever PS. The Kenyan Luo migration study: observations on the initiation of a rise in blood pressure. BMJ. 1990; 300: 967–972.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    Forte JG, Pereira Miguel JM, Pereira Miguel MJ, de Padua F, Rose G. Salt and blood pressure: a community trial. J Hum Hypertens. 1989; 3: 179–184.
    OpenUrlPubMed
  7. ↵
    Lifton RP. Molecular genetics of human blood pressure variations. Science. 1996; 272: 676–680.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    Denton D, Weisinger R, Mundy NI, Wickings EJ, Dixson A, Moisson P, Pingard AM, Shade R, Carey D, Ardaillou R, Paillard F, Chapman J, Thillet J, Michel JB. The effect of increased salt intake on blood pressure of chimpanzees. Nat Med. 1995; 1: 1009–1016.
    OpenUrlCrossRefPubMed
  9. ↵
    Midgley JP, Matthew AG, Greenwood CM, Logan AG. Effect of reduced dietary sodium on blood pressure: a meta-analysis of randomized controlled trials. JAMA. 1996; 275: 1590–1597.
    OpenUrlCrossRefPubMed
  10. ↵
    Cutler JA, Follmann D, Allender PS. Randomized trials of sodium reduction: an overview. Am J Clin Nutr. 1997; 65 (suppl): 643s–651s.
    OpenUrlPubMed
  11. ↵
    Graudal NA, Gallae AM, Garred P. Effect of sodium restriction on blood pressure, renin, aldosterone, catecholamines, cholesterols, and triglyceride: a meta-analysis. JAMA. 1998; 279: 1383–1391.
    OpenUrlCrossRefPubMed
  12. ↵
    Hooper L, Bartlett C, Davey Smith G, Ebrahim S. Systematic review of long term effects of advice to reduce dietary salt in adults. BMJ. 2002; 325: 628–634.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    Joint WHO/FAO expert consultation on diet, nutrition and the prevention of chronic diseases. 2003, Geneva. Available at http://www.who.int/hpr/NPH/docs/who_fao_experts_report.pdf. Accessed October 21, 2003.
  14. ↵
    Scientific Advisory Committee on Nutrition, Salt and Health. 2003. The Stationery Office. Available at http://www.sacn.gov.uk/pdf/saltfinal/pdf. Accessed October 21, 2003.
  15. ↵
    Whelton PK, He J, Appel LJ, Cutler JA, Havas S, Kotchen TA, Roccella EJ, Stout R, Vallbona C, Winston MC, Karimbakas J. National High Blood Pressure Education Program Coordinating Committee. Primary prevention of hypertension: clinical and public health advisory from The National High Blood Pressure Education Program. JAMA. 2002; 288: 1882–1888.
    OpenUrlCrossRefPubMed
  16. ↵
    Dahl KL, Knudsen KD, Heine MA, Leitl GJ. Effects of chronic excess salt ingestion: modification of experimental hypertension in the rat by variations in the diet. Circ Res. 1968; 22: 11–18.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    MacGregor GA, Markandu ND, Sagnella GA, Singer D, Cappuccio FP. Double-blind study of three sodium intakes and long-term effects of sodium restriction in essential hypertension. Lancet. 1989; 2: 1244–1247.
    OpenUrlCrossRefPubMed
  18. ↵
    Sacks FM, Svetkey LR, Vollmer WM, Appel LJ, Bray GA, Harsha D, Obarzanek E, Conlin PR, Miller ER, Simons-Morton DG, Karanja N, Lin PH. Effects on blood pressure of reduced dietary sodium and the dietary approaches to stop hypertension (DASH) diet. N Engl J Med. 2001; 344: 3–10.
    OpenUrlCrossRefPubMed
  19. ↵
    He FJ, MacGregor GA. Effect of modest salt reduction on blood pressure: a meta-analysis of randomised trials: implications for public health. J Hum Hypertens. 2002; 16: 761–770.
    OpenUrlCrossRefPubMed
  20. ↵
    Snedecor GW, Cochran WG. Statistical Methods. 8th ed. Ames, Iowa: Iowa State University Press; 1989: 149–176.
  21. ↵
    Parijs J, Joossens JV, der Linden LV, Verstreken G, Amery AKPC. Moderate sodium restriction and diuretics in the treatment of hypertension. Am Heart J. 1973; 85: 22–34.
    OpenUrlCrossRefPubMed
  22. ↵
    Morgan TO, Myer JB. Hypertension treated by sodium restriction. Med J Aust. 1981; 2: 396–397.
    OpenUrlPubMed
  23. ↵
    MacGregor GA, Markandu ND, Best FE, Elder DM, Cam JM, Sagnella GA, Squires M. Double-blind randomised crossover trial of moderate sodium restriction in essential hypertension. Lancet. 1982; 1: 351–355.
    OpenUrlPubMed
  24. ↵
    Watt GCM, Edward C, Hart JT, Heart M, Walton P, Foy CJW. Dietary sodium restriction for mild hypertension in general practice. BMJ. 1983; 286: 432–436.
    OpenUrlAbstract/FREE Full Text
  25. ↵
    Silman AJ, Locke C, Mitchell P, Humpherson P. Evaluation of the effectiveness of a low sodium diet in the treatment of mild to moderate hypertension. Lancet. 1983; 1: 1179–1182.
    OpenUrlPubMed
  26. ↵
    Puska P, Iacono JM, Nissinen A, Korhonen HJ, Vartiainen E, Pietinen P, Dougherty R, Leino U, Mutanen M, Moisio S, Huttunen J. Controlled, randomised trial of the effect of dietary fat on blood pressure. Lancet. 1983; 1: 1–5.
    OpenUrlPubMed
  27. ↵
    Richards AM, Nicholls MG, Espiner EA, Ikram H, Maslowski AH, Hamilton EJ, Wells JE. Blood-pressure response to moderate sodium restriction and to potassium supplementation in mild essential hypertension. Lancet. 1984; 1: 757–761.
    OpenUrlPubMed
  28. ↵
    Erwteman TM, Nagelkerke N, Lubsen J, Koster M, Dunning AJ. β-Blockade, diuretics, and salt restriction for the management of mild hypertension: a randomised double blind trial. BMJ. 1984; 289: 406–409.
    OpenUrlAbstract/FREE Full Text
  29. ↵
    Chalmers J, Morgan T, Doyle A, Dickson B, Hopper J, Mathews J, Matthews G, Moulds R, Myers J, Nowson C, Scoggins B, Stebbing M. Australian National Health and Medical Research Council dietary salt study in mild hypertension. J Hypertens. 1986; 4 (suppl 6): S629–S637.
    OpenUrl
  30. ↵
    Grobbee DE, Hofman A, Roelandt JT, Boomsma F, Schalekamp MA, Valkenburg HA. Sodium restriction and potassium supplementation in young people with mildly elevated blood pressure. J Hypertens. 1987; 5: 115–119.
    OpenUrlCrossRefPubMed
  31. ↵
    Australian National Health and Medical Research Council Dietary Salt Study Management Committee. Effects of replacing sodium intake in subjects on a low sodium diet: a crossover study. Clin Exp Hypertens. 1989; A11: 1011–1024.
    OpenUrl
  32. ↵
    Australian National Health and Medical Research Council Dietary Salt Study Management Committee. Fall in blood pressure with modest reduction in dietary salt intake in mild hypertension. Lancet. 1989; 1: 399–402.
    OpenUrlCrossRefPubMed
  33. ↵
    Benetos A, Yang Yan X, Cuche JL, Hannaert P, Safar M. Arterial effects of salt restriction in hypertensive patients: a 9-week, randomized, double-blind, crossover study. J Hypertens. 1992; 10: 355–360.
    OpenUrlCrossRefPubMed
  34. ↵
    Fotherby MD, Potter JF. Effects of moderate sodium restriction on clinic and twenty-four-hour ambulatory blood pressure in elderly hypertensive subjects. J Hypertens. 1993; 11: 657–663.
    OpenUrlCrossRefPubMed
  35. ↵
    Cappuccio FP, Markandu ND, Carney C, Sagnella GA, MacGregor GA. Double-blind randomised trial of modest salt restriction in older people. Lancet. 1997; 350: 850–854.
    OpenUrlCrossRefPubMed
  36. ↵
    Watt GC, Foy CJ, Hart JT, Bingham G, Edwards C, Hart M, Thomas E, Walton P. Dietary sodium and arterial blood pressure: evidence against genetic susceptibility. BMJ. 1985; 291: 1525–1528.
    OpenUrlAbstract/FREE Full Text
  37. ↵
    Mascioli S, Grimm RH, Launer C, Svendsen K, Flack J, Gonzalez N, Elmer P, Neaton J. Sodium chloride raises blood pressure in normotensive subjects: the study of sodium and blood pressure. Hypertension. 1991; 17 (suppl I): I-21–I-26.
    OpenUrlPubMed
  38. ↵
    Cobiac L, Nestel PJ, Wing LMH, Howe PRC. A low-sodium diet supplemented with fish oil lowers blood pressure in the elderly. J Hypertens. 1992; 10: 87–92.
    OpenUrlCrossRefPubMed
  39. ↵
    The Trials of Hypertension Prevention Collaborative Research Group. The effects of nonpharmacologic interventions on blood pressure of persons with high normal levels: results of the Trials of Hypertension Prevention, phase I. JAMA. 1992; 267: 1213–1220.
    OpenUrlCrossRefPubMed
  40. ↵
    Ruppert M, Overlack A, Kolloch R, Kraft K, Gobel B, Stumpe KO. Neurohormonal and metabolic effects of severe and moderate salt restriction in non-obese normotensive adults. J Hypertens. 1993; 117: 743–749.
    OpenUrl
  41. ↵
    Nestel PJ, Clifton PM, Noakes M, McArthur R, Howe PR. Enhanced blood pressure response to dietary salt in elderly women, especially those with small waist:hip ratio. J Hypertens. 1993; 11: 1387–1394.
    OpenUrlPubMed
  42. ↵
    Schorr U, Distler A, Sharma AM. Effect of sodium chloride- and sodium bicarbonate-rich mineral water on blood pressure and metabolic parameters in elderly normotensive individuals: a randomized double-blind crossover trial. J Hypertens. 1996; 14: 131–135.
    OpenUrlPubMed
  43. ↵
    The Trials of Hypertension Prevention Collaborative Research Group. Effect of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure: The Trials of Hypertension Prevention, Phase II. Arch Intern Med. 1997; 157: 657–667.
    OpenUrlCrossRefPubMed
  44. ↵
    Henderson L, Irving K, Gregory J, Bates CJ, Prentice A, Perks J, Swan G, Farron M. National Diet and Nutrition Survey: Adults Aged 19 to 64. 2003: 3: 127–136.
  45. ↵
    Pietinen P. Estimating sodium intake from food consumption data. Ann Nutr Metab. 1982; 26: 90–99.
    OpenUrlCrossRefPubMed
  46. ↵
    Coronary heart disease statistics. British Heart Foundation Statistics Database 2002. http://www.dphpc.ox.ac.uk/bhfhprg/stats/2000/index.html. Accessed December 17, 2002.
  47. ↵
    Law MR, Frost CD, Wald NJ. By how much does dietary salt reduction lower blood pressure? I-Analysis of observational data among populations. BMJ. 1991; 302: 811–815.
    OpenUrlAbstract/FREE Full Text
  48. ↵
    Nestle M. Food Politics: How the Food Industry Influences Nutrition and Health. London, England: University of California Press; 2002.
View Abstract
Back to top
Previous ArticleNext Article

This Issue

Hypertension
December 2003, Volume 42, Issue 6
  • Table of Contents
Previous ArticleNext Article

Jump to

  • Article
    • Abstract
    • Methods
    • Results
    • Discussion
    • Acknowledgments
    • References
  • Figures & Tables
  • Info & Metrics
  • eLetters

Article Tools

  • Print
  • Citation Tools
    How Far Should Salt Intake Be Reduced?
    Feng J. He and Graham A. MacGregor
    Hypertension. 2003;42:1093-1099, originally published December 11, 2003
    https://doi.org/10.1161/01.HYP.0000102864.05174.E8

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
  •  Download Powerpoint
  • Article Alerts
    Log in to Email Alerts with your email address.
  • Save to my folders

Share this Article

  • Email

    Thank you for your interest in spreading the word on Hypertension.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    How Far Should Salt Intake Be Reduced?
    (Your Name) has sent you a message from Hypertension
    (Your Name) thought you would like to see the Hypertension web site.
  • Share on Social Media
    How Far Should Salt Intake Be Reduced?
    Feng J. He and Graham A. MacGregor
    Hypertension. 2003;42:1093-1099, originally published December 11, 2003
    https://doi.org/10.1161/01.HYP.0000102864.05174.E8
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Related Articles

Cited By...

Subjects

  • Basic, Translational, and Clinical Research
    • Clinical Studies

Hypertension

  • About Hypertension
  • Instructions for Authors
  • AHA CME
  • Guidelines and Statements
  • Permissions
  • Journal Policies
  • Email Alerts
  • Open Access Information
  • AHA Journals RSS
  • AHA Newsroom

Editorial Office Address:
7272 Greenville Ave.
Dallas, TX 75231
email: hypertension@heart.org

Information for:
  • Advertisers
  • Subscribers
  • Subscriber Help
  • Institutions / Librarians
  • Institutional Subscriptions FAQ
  • International Users
American Heart Association Learn and Live
National Center
7272 Greenville Ave.
Dallas, TX 75231

Customer Service

  • 1-800-AHA-USA-1
  • 1-800-242-8721
  • Local Info
  • Contact Us

About Us

Our mission is to build healthier lives, free of cardiovascular diseases and stroke. That single purpose drives all we do. The need for our work is beyond question. Find Out More about the American Heart Association

  • Careers
  • SHOP
  • Latest Heart and Stroke News
  • AHA/ASA Media Newsroom

Our Sites

  • American Heart Association
  • American Stroke Association
  • For Professionals
  • More Sites

Take Action

  • Advocate
  • Donate
  • Planned Giving
  • Volunteer

Online Communities

  • AFib Support
  • Garden Community
  • Patient Support Network
  • Professional Online Network

Follow Us:

  • Follow Circulation on Twitter
  • Visit Circulation on Facebook
  • Follow Circulation on Google Plus
  • Follow Circulation on Instagram
  • Follow Circulation on Pinterest
  • Follow Circulation on YouTube
  • Rss Feeds
  • Privacy Policy
  • Copyright
  • Ethics Policy
  • Conflict of Interest Policy
  • Linking Policy
  • Diversity
  • Careers

©2018 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. The American Heart Association is a qualified 501(c)(3) tax-exempt organization.
*Red Dress™ DHHS, Go Red™ AHA; National Wear Red Day ® is a registered trademark.

  • PUTTING PATIENTS FIRST National Health Council Standards of Excellence Certification Program
  • BBB Accredited Charity
  • Comodo Secured